



[Tweetorial: Improving Clinician Awareness of #RettSyndrome
and Optimizing Management of Care Across the Patient Lifespan](#)

January 26, 2023

[VIEW ON TWITTER](#)

ACCREDITATION STATEMENT

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

FACULTY AFFILIATIONS

Alan Percy, MD

University of Alabama at
Birmingham –
Children’s Hospital of Alabama
Birmingham, AL

Jane Lane, RN, BSN

University of Alabama at
Birmingham –
Pediatric Neurology
Birmingham, AL

Amitha Ananth, MD

University of Alabama at
Birmingham –
Children’s Hospital of Alabama
Birmingham, AL

FINANCIAL DISCLOSURE

The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:

Dr Percy has served as a consultant for Acadia Pharmaceuticals.

Dr Ananth has received research support from Acadia Pharmaceuticals and Anavex Life Sciences.

Mrs. Lane has no disclosures.

Michael R. Page, PharmD, RPh

Independent Medical Director/Medical Writer
Plainsboro, New Jersey

Dr. Page is a consultant for BioCentric, Inc. and American Medical Communications, Inc.

None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.



TWEETORIAL REFERENCES

Slide #7

Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. *Ann Neurol*. 2010;68(6):944-950. <https://doi.org/10.1002/ana.22124>

Slide #8

Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet*. 1999;23(2):185-188. <https://doi.org/10.1038/13810>

Slide #9

Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. *Ann Neurol*. 2010;68(6):944-950. <https://doi.org/10.1002/ana.22124>

Slide #10

Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. *BMJ Paediatr Open*. 2020;4(1):e000717. Published 2020 Sep 13. <http://dx.doi.org/10.1136/bmjpo-2020-000717>

Slide #11

Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. *BMJ Paediatr Open*. 2020;4(1):e000717. Published 2020 Sep 13. <http://dx.doi.org/10.1136/bmjpo-2020-000717>

Slide #12

Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. *Ann Neurol*. 2010;68(6):944-950. <https://doi.org/10.1002/ana.22124>

Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. *BMJ Paediatr Open*. 2020;4(1):e000717. Published 2020 Sep 13. <http://dx.doi.org/10.1136/bmjpo-2020-000717>

Slide #13

Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. *BMJ Paediatr Open*. 2020;4(1):e000717. Published 2020 Sep 13. <http://dx.doi.org/10.1136/bmjpo-2020-000717>

Kyle SM, Vashi N, Justice MJ. 2018 Rett syndrome: a neurological disorder with metabolic components. *Open Biol*.8:170216. <https://doi.org/10.1098/rsob.170216>

Slide #14

Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. *BMJ Paediatr Open*. 2020;4(1):e000717. Published 2020 Sep 13. <http://dx.doi.org/10.1136/bmjpo-2020-000717>



Slide #15

Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. *BMJ Paediatr Open*. 2020;4(1):e000717. Published 2020 Sep 13. <http://dx.doi.org/10.1136/bmjpo-2020-000717>

Slide #16

Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome. <https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3-lavender-trial-of-trofinetide-in-rett-syndrome/>. Published December 6, 2021. Accessed December 26, 2022.

BioSpace. ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome. <https://www.biospace.com/article/releases/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints-for-the-treatment-of-adult-patients-with-rett-syndrome/>. Published February 1, 2022. Accessed December 26, 2022.

Gadalla KKE, Ross PD, Hector RD, et al. Gene therapy for Rett syndrome: prospects and challenges. *Future Neurology*. 2015;10(5): <https://doi.org/10.2217/fnl.15.29>.

Slide #17

Acadia. Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome. <https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3-lavender-trial-of-trofinetide-in-rett-syndrome/>. Published December 6, 2021. Accessed December 26, 2022.

Yuan ZF, Mao SS, Shen J, et al. Insulin-Like Growth Factor-1 Down-Regulates the Phosphorylation of FXRD1 and Rescues Behavioral Deficits in a Mouse Model of Rett Syndrome. *Front Neurosci*. 2020;14:20. Published 2020 Jan 29. <https://doi.org/10.3389/fnins.2020.00020>

Slide #18

Acadia. Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome. <https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3-lavender-trial-of-trofinetide-in-rett-syndrome/>. Published December 6, 2021. Accessed December 26, 2022.

ClinicalTrials.gov. Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) - Full Text View -. <https://clinicaltrials.gov/ct2/show/NCT04181723>. Accessed December 26, 2022.

Slide #19

Acadia. Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome. <https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3-lavender-trial-of-trofinetide-in-rett-syndrome/>. Published December 6, 2021. Accessed December 26, 2022.

Slide #20

BioSpace. ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome. <https://www.biospace.com/article/releases/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints-for-the-treatment-of-adult-patients-with-rett-syndrome/>. Published February 1, 2022. Accessed December 26, 2022.

Slide #21

BioSpace. ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome. <https://www.biospace.com/article/releases/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints-for-the-treatment-of-adult-patients-with-rett-syndrome/>. Published February 1, 2022. Accessed December 26, 2022.

Slide #22

Gadalla KKE, Ross PD, Hector RD, et al. Gene therapy for Rett syndrome: prospects and challenges. *Future Neurology*. 2015;10(5): <https://doi.org/10.2217/fnl.15.29>.

ClinicalTrials.gov. Open-label, Randomized, Dose-escalation and Dose-expansion Study of the Safety and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, in the Treatment of Adult Females With Rett Syndrome - Full Text View -. <https://clinicaltrials.gov/ct2/show/NCT05606614>. Accessed December 26, 2022.

Leonard, H., Gold, W., Samaco, R. et al. Improving clinical trial readiness to accelerate development of new therapeutics for Rett syndrome. *Orphanet J Rare Dis*. 2022;17:108. <https://doi.org/10.1186/s13023-022-02240-w>

GLOSSARY

ADAMS	Anxiety, Depression, and Mood Scale
CDKL5	Cyclin dependent kinase like 5
CGI-I	Clinical Global Impression-Improvement
ER	Endoplasmic reticulum
FOXG1	Forkhead-box G1
IGF-1	Insulin-like growth factor-1
MECP2	Methyl-CpG-binding protein 2
MLPA	Multiplex ligation-dependent probe amplification
RSBQ	Rett Syndrome Behavior Questionnaire
RTT	Rett syndrome